RAMON - RAdical Management Of Advanced Non-small cell lung cancer
Research type
Research Study
Full title
Multi-modality local consolidative treatment versus conventional care of advanced lung cancer after first line systemic anti-cancer treatment: a multi-centre randomised controlled trial with an internal pilot
IRAS ID
308485
Contact name
Eric Lim
Contact email
Sponsor organisation
Royal Brompton & Harefield Hospitals, Guy’s and St Thomas’ NHS Foundation Trust
ISRCTN Number
ISRCTN11613852
Duration of Study in the UK
6 years, months, days
Research summary
Lung cancer is the most common cause of cancer death worldwide, and the majority of patients in the UK present with advanced disease. One-year survival is improving but remains low at 37% despite new treatments which now form the current standard of care for advanced lung cancer. Although these new therapies are very good, some cancer persists in most patients after treatment (termed ‘residual cancer’) and little is known on how best to deal with it. As such, management of residual advanced lung cancer varies across the UK, with some patients receiving only symptom management while others go on to have treatment in the form of surgery, radiotherapy and/or ablation with the aim to remove all remaining cancer within the lung and throughout the body. Collectively, these treatments are known as ‘local consolidative treatment’ (LCT). LCT is intensive, impacts quality of life and is expensive but most importantly, we do not know if it results in a better outcome for patients.
The aim of the RAMON study is to find out whether LCT alongside symptom management is worthwhile (or not) for patients with residual advanced lung cancer. Patients who agree to join the study will be divided into two equal sized groups. One group will receive LCT alongside symptom management and the other group will receive symptom management alone. The study will compare overall survival and quality of life between the two groups, as well as comparing the cost-effectiveness to the NHS.
The study will aim to recruit 244 participants from 40 secondary and tertiary care NHS hospitals.
REC name
West of Scotland REC 3
REC reference
22/WS/0121
Date of REC Opinion
23 Aug 2022
REC opinion
Favourable Opinion